Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt and Other Financings (Tables)

v3.21.1
Long-Term Debt and Other Financings (Tables)
3 Months Ended
Mar. 31, 2021
Long-Term Debt and Other Financings  
Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt

Aggregate future principal, final payment fees and discounts of the Company’s long-term debt as of March 31, 2021, are as follows (in thousands):

March 31, 

2021

2021 (excluding three months ended March 31, 2021)

$

6,290

2022

13,523

Thereafter

Total payments

19,813

Less: interest, final payment fees, discount and issuance costs

(958)

Total payments, net of interest, final payment fees, discount and issuance costs

18,855

Less: current portion of long-term debt

(7,201)

Long-term debt

 

$

11,654

Interest Expense and Amortization of Debt Issuance Costs and Discounts

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive loss relates to the following debt instruments (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

SVB loan

$

238

$

383

Novartis note

 

51

 

158

Other

 

 

1

Total interest expense

$

289

$

542